An observational study in Acute Myelogenous Leukemia and Chemotherapy, sponsored by Shenzhen People's Hospital. Status unknown at 1 site in China. Open to participants aged 14 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-18.
Sponsored by Shenzhen People's Hospital · Observational
By observation of the inpatients in shenzhen people's hospital,research the curative effect of the two chemotherapy schemes on AML-High dose of cytarabine and HAM.
The patients of AML in shenzhen people's hospital were randomly divided into two therapy groups.One group was treated by High dose of cytarabine ,and the other was HAM.Evaluate the two chemotherapy schemes by bone marrow suppression time and patient survival time.
5,441 studies on the registry are indexed under Leukemia; 637 are open to participants now.
This study's planned enrollment of 250 is above the median of 120 across 744 observational studies indexed under Leukemia.
Browse Leukemia studies →Shenzhen People's Hospital is the lead sponsor of 62 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
people diagnosed as AML expect acute promyeloytic leukemia
people diagnosed as AML
Exclusion Criteria:
high dose of cytarabine
Device: Flow Cytometer · Drug: Mitoxantrone · Drug: Cytarabine
medium dose of cytarabine and mitoxantrone
Device: Flow Cytometer · Drug: Mitoxantrone · Drug: Cytarabine
high dose
high dose
high dose
bone marrow suppression time
time of agranulocytosis
Time frame: one month
patient survival time
disease free survival
Time frame: three years
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shenzhen People's Hospital